Globus Medical's preliminary Q4 sales beat estimates

Globus Medical

07/01/2026 21:38

Overview

Musculoskeletal solutions company's preliminary Q4 sales rose 25.2%, beating analyst expectations

Company's results driven by growth in US Spine and Enabling Technologies divisions

Company successfully integrated NuVasive and Nevro acquisitions

Outlook

Company expects 2026 revenue between $3.18 bln and $3.22 bln

Globus Medical forecasts 2026 non-GAAP EPS between $4.30 and $4.40

Result Drivers

US SPINE GROWTH - Co attributed Q4 sales growth to gains in US Spine market

ENABLING TECHNOLOGIES PERFORMANCE - Enabling Technologies division achieved its best quarterly revenue to date

ACQUISITION INTEGRATION - Successful integration of NuVasive and Nevro acquisitions contributed to Q4 growth

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Sales
Beat
$823.20 mln
$777.35 mln (13 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Globus Medical Inc is $99.00, about 6.1% above its January 6 closing price of $93.29

Press Release: ID:nGNX5yb6kf

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)